About US
Contact us
-
Sartorius Stedim Biotech Expands PAT Software Portolio for Optimization of Biopharmaceutical Development and Manufacturing ProcessesSartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer. Umetrics is2012/12/20
-
Judge blocks Endo's effort to block generic pain medsEndo Health Solutions' ($ENDO) attempt to outmaneuver generic competition by kicking dirt all over its own product has come up short. A federal judge in Washington declined to force the FDA to declar2012/12/20
-
UPDATE: Amgen pleads guilty in $762M Aranesp settlementAmgen's ($AMGN) long-brewing settlement with the U.S. Justice Department is close at hand. The drugmaker pleaded guilty today to a misdemeanor misbranding charge for mismarketing its anemia drug Arane2012/12/19
-
Valeant cuts 200 Medicis jobs as $2.6B deal closesValeant Pharmaceuticals ($VRX) isn't pussyfooting around Medicis. As the built-by-acquisition Canadian company wrapped up its deal for Medicis last week, some 200 employees were told to pack their ba2012/12/19
-
WIN Consortium announces collaboration with PfizerPfizer has become the first pharmaceutical partner of the Worldwide Innovative Network (WIN) Consortium - a global network of academic, industry and patient advocacy organisations working to advance2012/12/18
-
Novartis orphan drug Signifor gets another approvalDrugmakers are seeing more market potential in orphan drugs, and drug regulators are rewarding them with approvals. The FDA has for the second time this year approved an orphan drug for the rare Cush2012/12/18
-
Roche looks to earn even more from Perjeta with EU nodRoche ($RHHBY) breast cancer drug Herceptin has been so effective that it earns the Swiss drugmaker boatloads of money. And Roche today tightened its lock on the breast cancer treatment market, and i2012/12/17
-
Ariad's potential blockbuster Iclusig gets early FDA OKAfter fast-tracking it, the FDA approved Ariad Pharmaceuticals' ($ARIA) closely watched leukemia drug ponatinib today, a product that analysts say could generate blockbuster sales. The FDA said Iclus2012/12/17
-
AstraZeneca, Lilly feeling real pain in race for arthritis drugsThe supercharged race to get new treatments into the lucrative market for treating rheumatoid arthritis (RA) appeared to thin considerably today as one contender dropped a study and another's drug cam2012/12/14
-
With FDA drug app in, Lundbeck gets much-needed good newsThere was a glimmer of good news today for Lundbeck, which has been slashing its payroll and its earnings projections as it wrestles with the patent loss of blockbuster Lexapro. The FDA has accepted2012/12/14